BioSpace News Archive

QYNAPSE Inc. is pleased to participate in the Sachs 4th Annual Neuroscience Innovation Forum on April 28-30, 2021, to present the latest advances in its solutions, which are transforming clinical care and clinical trials for patients with brain disorders, such as Alzheimer’s, Parkinson’s and Multiple Sclerosis.

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2021 financial results before the market opens on Wednesday, May 5, 2021 . United Therapeutics will host a teleconference on Wednesday, May 5, 2021 , at 9:00 a.m. Eastern Time .

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it will release financial results for the first quarter ended March 31, 2021 after the close of trading on Tuesday, May 11.

Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein.

The study aims to further validate the anti-fibrotic and anti-inflammatory activity of CM-101 while providing safety and PK data to support development of the subcutaneous formulation

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced that data from its two pivotal Phase 3 trials of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II will be presented at the upcoming American Psychiatric Association Annual Meeting.

Microbix Biosystems Inc., a life sciences innovator and exporter, and SpeeDx Pty. Ltd., a developer of innovative molecular diagnostics solutions, are pleased to announce the formation of a collaboration under which Microbix will be exclusive developer of Quality Assessment Products to facilitate the registration and commercialization of SpeeDx diagnostic assays.

Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the B. Riley Securities’ Virtual Neuroscience Conference on Wednesday, April 28, 2021 at 12:00 p.m. EDT.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that it will release its first quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, May 6, 2021.

Neurolutions, Inc., a medical device company developing and commercializing a first-of-its-kind device leveraging brain-computer interface (BCI) technology for upper extremity chronic stroke rehabilitation, announced today that the U.S. Food and Drug Administration (FDA) granted De Novo market authorization for its groundbreaking IpsiHand Upper Extremity Rehabilitation System.